STUDY TO EVALUATE PSORIASIS SEVERITY AND ITS PSYCHOSOCIAL IMPACT USING THE SIMPLIFIED PSORIASIS INDEX (SPI), AS WELL AS LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SECUKINUMAB ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: